IPO - Cabaletta Bio, Inc.

Form Type: 424B5

Filing Date: 2025-06-12

Corporate Action: Ipo

Type: New

Accession Number: 000119312525139512

Filing Summary: Cabaletta Bio, Inc. is conducting an initial public offering of 39,200,000 shares of its common stock, with pre-funded warrants allowing the purchase of 10,800,000 additional shares and warrants for up to 50,000,000 shares of common stock. The offering price for common shares is $2.00 each, while pre-funded warrants are priced at approximately $1.99999. Total proceeds expected before expenses are approximately $93,999,892. The common stock warrants have a $2.50 exercise price, are immediately separable and exercisable, expiring fifteen months from issuance. The pre-funded warrants are not expected to develop a public trading market. The FDA has granted multiple designations to their lead product candidate, rese-cel, indicating potential pathways forward in treating various autoimmune diseases. The offer is made through a shelf registration statement under Rule 424(b)(5), indicating the company’s readiness to adapt to market conditions and investor interest.

Form Type: 8-K

Filing Date: 2025-06-12

Corporate Action: Ipo

Type: New

Accession Number: 000119312525139517

Filing Summary: On June 11, 2025, Cabaletta Bio, Inc. entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, and Cantor Fitzgerald & Co. for an underwritten offering. The offering includes 39,200,000 shares of common stock and pre-funded warrants to purchase an additional 10,800,000 shares. The company also issued accompanying warrants to purchase an aggregate of 50,000,000 shares. The offering price is set at $2.00 per share and $1.99999 per pre-funded warrant, with a closing expected on June 12, 2025. The net proceeds from the offering are estimated at approximately $94.0 million, which will fund clinical development and enhance manufacturing capabilities. The Underwriting Agreement includes standard representations and warrants, and attachments provide further legal context and a press release concerning the offering.